Profile data is unavailable for this security.
About the company
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Women’s Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.
- Revenue in USD (TTM)25.05m
- Net income in USD-49.46m
- Incorporated2015
- Employees54.00
- LocationElutia Inc12510 PROSPERITY DRIVE, SUITE 370SILVER SPRING 20904United StatesUSA
- Phone+1 (240) 247-1143
- Fax+1 (510) 307-9896
- Websitehttps://elutia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earth Science Tech Inc | 5.98m | 330.94k | 78.71m | 8.00 | 260.42 | 36.47 | 148.72 | 13.15 | 0.001 | 0.001 | 0.0195 | 0.0069 | 3.16 | 11.41 | 106.07 | 747,970.00 | 17.50 | -224.84 | 42.70 | -- | 62.29 | 37.79 | 5.53 | -333.58 | 0.386 | -0.3899 | 0.1023 | -- | 243.77 | -36.31 | -111.95 | -- | -- | -- |
| BioXcel Therapeutics Inc | 1.76m | -153.05m | 78.81m | 74.00 | -- | -- | -- | 44.88 | -5.18 | -5.18 | 0.0591 | -2.15 | 0.0134 | 0.6067 | 5.31 | 23,729.73 | -116.64 | -74.57 | -151.39 | -84.06 | 24.15 | -- | -8,715.72 | -32,300.74 | 2.49 | -15.67 | 3.47 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -15.40m | 79.38m | 9.00 | -- | 4.02 | -- | -- | -0.1496 | -0.1496 | 0.00 | 0.1914 | 0.00 | -- | -- | 0.00 | -40.89 | -- | -50.40 | -- | -- | -- | -- | -- | -- | -2,083.71 | 0.0183 | -- | -- | -- | 34.25 | -- | -- | -- |
| Aileron Therapeutics Inc | 0.00 | -18.07m | 79.67m | 15.00 | -- | 1.39 | -- | -- | -3.19 | -3.19 | 0.00 | 5.42 | 0.00 | -- | -- | 0.00 | -31.05 | -65.99 | -33.17 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
| Provectus Biopharmaceuticals Inc | 590.75k | -2.78m | 79.71m | 4.00 | -- | -- | -- | 134.93 | -0.0066 | -0.0066 | 0.0014 | -0.0178 | 0.4221 | -- | 1,358.05 | 147,687.50 | -198.50 | -276.33 | -- | -- | -- | -- | -470.31 | -1,667.76 | -- | -10.24 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
| Passage Bio Inc | 0.00 | -84.44m | 80.71m | 58.00 | -- | 0.7695 | -- | -- | -1.53 | -1.53 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -47.73 | -48.56 | -52.17 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
| Elutia Inc | 25.05m | -49.46m | 81.82m | 54.00 | -- | -- | -- | 3.27 | -2.35 | -2.34 | 1.24 | -2.07 | 0.5219 | 2.06 | 4.27 | 463,833.30 | -103.05 | -42.93 | -599.50 | -79.34 | 42.01 | 43.32 | -197.48 | -64.16 | 0.5499 | -1.36 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
| Assembly Biosciences Inc | 12.95m | -51.36m | 82.48m | 65.00 | -- | 2.52 | -- | 6.37 | -11.22 | -11.22 | 2.76 | 5.95 | 0.1276 | -- | 34.07 | 199,200.00 | -50.60 | -39.69 | -66.58 | -44.03 | -- | -- | -396.63 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| Spero Therapeutics Inc | 110.98m | 23.40m | 84.07m | 46.00 | 3.70 | 0.8731 | 3.55 | 0.7576 | 0.4213 | 0.4213 | 2.08 | 1.79 | 0.792 | -- | 3.96 | 2,412,565.00 | 16.70 | -35.52 | 21.73 | -41.75 | -- | -- | 21.09 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| Cognition Therapeutics Inc | 0.00 | -28.77m | 84.12m | 25.00 | -- | 2.91 | -- | -- | -0.9155 | -0.9155 | 0.00 | 0.7218 | 0.00 | -- | -- | 0.00 | -68.08 | -- | -85.18 | -- | -- | -- | -- | -- | -- | -251.59 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
| Serina Therapeutics Inc | 137.00k | -20.96m | 84.14m | 4.00 | -- | -- | -- | 614.15 | -14.07 | -14.07 | 0.0909 | -0.5121 | 0.0117 | -- | 3.86 | 34,250.00 | -179.27 | -194.46 | -- | -- | 67.88 | 85.80 | -15,301.46 | -2,347.36 | -- | -0.9274 | 1.70 | -- | 317.65 | -36.69 | -41.49 | -- | -- | -- |
| Aclaris Therapeutics Inc | 31.12m | -77.26m | 84.81m | 91.00 | -- | 0.597 | -- | 2.73 | -1.09 | -1.09 | 0.4392 | 1.99 | 0.1541 | -- | 58.77 | 341,967.00 | -38.27 | -47.29 | -42.29 | -53.87 | 41.99 | 44.00 | -248.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| vTv Therapeutics Inc | 1.00m | -20.62m | 84.92m | 16.00 | -- | 4.08 | -- | 84.92 | -8.76 | -8.76 | 0.383 | 6.91 | 0.0241 | -- | 2.04 | 62,500.00 | -63.15 | -111.84 | -128.59 | -- | -- | -- | -2,621.10 | -680.94 | -- | -- | 0.00 | -- | -100.00 | -- | -5.67 | -- | -- | -- |
Data as of May 20 2024. Currency figures normalised to Elutia Inc's reporting currency: US Dollar USD
26.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Birchview Capital LPas of 31 Mar 2024 | 1.66m | 8.26% |
| Nantahala Capital Management LLCas of 31 Mar 2024 | 1.65m | 8.24% |
| Perkins Capital Management, Inc.as of 31 Mar 2024 | 797.60k | 3.98% |
| AIGH Capital Management LLCas of 31 Mar 2024 | 436.57k | 2.18% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 415.71k | 2.08% |
| Geode Capital Management LLCas of 31 Mar 2024 | 118.31k | 0.59% |
| SilverArc Capital Management LLCas of 31 Mar 2024 | 78.58k | 0.39% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 35.62k | 0.18% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 23.58k | 0.12% |
| Millennium Management LLCas of 31 Mar 2024 | 19.46k | 0.10% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
